341 related articles for article (PubMed ID: 37126968)
1. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
2. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
3. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract][Full Text] [Related]
4. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.
Bricelj A; Steinebach C; Kuchta R; Gütschow M; Sosič I
Front Chem; 2021; 9():707317. PubMed ID: 34291038
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
[TBL] [Abstract][Full Text] [Related]
6. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
[TBL] [Abstract][Full Text] [Related]
7. Development of Rapid and Facile Solid-Phase Synthesis of PROTACs via a Variety of Binding Styles.
Xu H; Kurohara T; Takano R; Yokoo H; Shibata N; Ohoka N; Inoue T; Naito M; Demizu Y
ChemistryOpen; 2022 Jul; 11(7):e202200131. PubMed ID: 35822913
[TBL] [Abstract][Full Text] [Related]
8. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
[TBL] [Abstract][Full Text] [Related]
9. E3 ligase ligand optimization of Clinical PROTACs.
Jiang H; Xiong H; Gu SX; Wang M
Front Chem; 2023; 11():1098331. PubMed ID: 36733714
[TBL] [Abstract][Full Text] [Related]
10. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
[TBL] [Abstract][Full Text] [Related]
11. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
12. A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions.
Guo L; Zhou Y; Nie X; Zhang Z; Zhang Z; Li C; Wang T; Tang W
Eur J Med Chem; 2022 Jun; 236():114317. PubMed ID: 35397401
[TBL] [Abstract][Full Text] [Related]
13. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
14. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
[TBL] [Abstract][Full Text] [Related]
15. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
16. Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs.
Shah RR; De Vita E; Sathyamurthi PS; Conole D; Zhang X; Fellows E; Dickinson ER; Fleites CM; Queisser MA; Harling JD; Tate EW
J Med Chem; 2024 Mar; 67(6):4641-4654. PubMed ID: 38478885
[TBL] [Abstract][Full Text] [Related]
17. CRBN ligand expansion for hematopoietic prostaglandin D
Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
[TBL] [Abstract][Full Text] [Related]
18. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs).
Baker IM; Smalley JP; Sabat KA; Hodgkinson JT; Cowley SM
Biochemistry; 2023 Feb; 62(3):645-656. PubMed ID: 35948047
[TBL] [Abstract][Full Text] [Related]
20. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
